• Dépistage, diagnostic, pronostic

  • Découverte de technologies et de biomarqueurs

Drug-eluting microarrays to identify effective chemotherapeutic combinations targeting patient-derived cancer stem cells

Menée in vitro à l'aide de cellules souches cancéreuses cultivées après avoir été isolées à partir d'échantillons tumoraux prélevés sur des patients, cette étude évalue la faisabilité et l'efficacité d'une biopuce permettant de tester la réponse de ces cellules à divers agents cytotoxiques, seuls ou en combinaison

A new paradigm in oncology establishes a spectrum of tumorigenic potential across the heterogeneous phenotypes within a tumor. The cancer stem cell hypothesis postulates that a minute fraction of cells within a tumor, termed cancer stem cells (CSCs), have a tumor-initiating capacity that propels tumor growth. An application of this discovery is to target this critical cell population using chemotherapy; however, the process of isolating these cells is arduous, and the rarity of CSCs makes it difficult to test potential drug candidates in a robust fashion, particularly for individual patients. To address the challenge of screening drug libraries on patient-derived populations of rare cells, such as CSCs, we have developed a drug-eluting microarray, a miniaturized platform onto which a minimal quantity of cells can adhere and be exposed to unique treatment conditions. Hundreds of drug-loaded polymer islands acting as drug depots colocalized with adherent cells are surrounded by a nonfouling background, creating isolated culture environments on a solid substrate. Significant results can be obtained by testing <6% of the cells required for a typical 96-well plate. Reliability was demonstrated by an average coefficient of variation of 14% between all of the microarrays and 13% between identical conditions within a single microarray. Using the drug-eluting array, colorectal CSCs isolated from two patients exhibited unique responses to drug combinations when cultured on the drug-eluting microarray, highlighting the potential as a prognostic tool to identify personalized chemotherapeutic regimens targeting CSCs.

Proceedings of the National Academy of Sciences , résumé, 2015

Voir le bulletin